Scholar Rock rallies 9% as FDA approval of its muscle-targeted therapy for spinal muscular atrophy prompts a wave of analyst price target upgrades.
FDA approval of ISEMBYLD and multiple analyst price target increases drive bullish sentiment.
S&P 500 declined 0.7% during a weaker session for US equities.
Dow Jones fell 0.2% amid broader market weakness.
Nasdaq down 1.7% as tech stocks underperformed.
Scholar Rock Holding Corp shares surged 9.1% to $60.45 in pre-market trading after the FDA approved ISEMBYLD for spinal muscular atrophy. The approval, which arrived ahead of the 2026 PDUFA deadline, triggered multiple analyst price target hikes, including moves from Truist, Raymond James, and Citi. The company now enters the commercial stage with $492 million in cash to support the launch.
The approval of ISEMBYLD marks Scholar Rock's transition into a commercial-stage company, providing a first-in-class muscle-targeted treatment for spinal muscular atrophy patients.